FIELD: biotechnologies.
SUBSTANCE: invention refers to ligands in the form of synthetic peptide amides of a kappa-opiate receptor, and namely to agonists of the kappa-opiate receptor, which show a low inhibition degree of P450 CYP and a low degree of penetration into brain. According to the invention, synthetic peptide amide is described by the following formula:
EFFECT: pharmaceutical compositions containing the above compounds are suitable for prophylaxis and curing of pain and inflammation, which are related to different diseases and states.
19 cl, 11 dwg, 53 ex
Title | Year | Author | Number |
---|---|---|---|
SYNTHETIC PEPTIDE AMIDES | 2007 |
|
RU2500685C2 |
HYDANTOIN MODIFIED MELANOCORTIN RECEPTOR LIGANDS | 2008 |
|
RU2450017C2 |
METASTIN DERIVATIVES AND USE THEREOF | 2007 |
|
RU2454425C2 |
PEPTIDE ANALOG OF ACYLATED OXYNTOMODULIN | 2018 |
|
RU2752787C1 |
METASTIN DERIVATIVES AND APPLICATION THEREOF | 2006 |
|
RU2430107C2 |
GLUCAGON ANALOGUES, POSSESSING HIGHER SOLUBILITY AND STABILITY IN BUFFERS WITH PHYSIOLOGICAL Ph VALUES | 2009 |
|
RU2560254C2 |
LINEAR OR CYCLIC OLIGOPEPTIDES SHOWING AFFINITY TO OPIATE RECEPTORS, PHARMACEUTICAL COMPOSITION | 1993 |
|
RU2131438C1 |
GIP AGONIST COMPOUNDS AND METHODS | 2015 |
|
RU2716985C2 |
PEPTIDE COMPOSITIONS | 2014 |
|
RU2725150C2 |
AMIDE-BASED PRODRUGS OF GLUCAGON SUPERFAMILY PEPTIDES | 2009 |
|
RU2550696C2 |
Authors
Dates
2014-03-27—Published
2007-11-13—Filed